Dietary polyphenols and mechanisms of osteoarthritis

Journal of Nutritional Biochemistry

Volumn 23, Issue 11, 2012, Pages 1367-1377

  Shen, Chwan Li ^a   Smith, Brenda J ^b   Lo, Di Fan ^a   Chyu, Ming Chien ^a,c   Dunn, Dale M ^a   Chen, Chung Hwan ^d   Kwun, In Sook ^e  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b OKLAHOMA STATE UNIVERSITY   (United States)

^c Department of Electrical and Computer Engineering   (United States)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e Andong National University   (South Korea)

Author keywords

Antioxidant; Inflammation; Molecular mechanism; Osteoarthritis; Pain management; Polyphenols

Indexed keywords

BAVACHIN; CITROFEN; COLLAGENASE 3; CURCUMA LONGA EXTRACT; CURCUMIN; CYCLOOXYGENASE 2; DAIDZEIN; EPIGALLOCATECHIN GALLATE; FLAVOXINE; GENISTEIN; GLYCITEIN; GREEN TEA EXTRACT; IBUPROFEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; NOBILETIN; NP 061; PHYTOESTROGEN; PLACEBO; PLANT EXTRACT; POLYPHENOL; POMEGRANATE EXTRACT; PROSTAGLANDIN E2; RESVERATROL; SOYBEAN PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICULAR CARTILAGE; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL PROTECTION; CITRUS FRUIT; CONTROLLED CLINICAL TRIAL (TOPIC); DISABILITY; DRUG MECHANISM; ERYTHROCYTE SEDIMENTATION RATE; FUNCTIONAL ASSESSMENT; HUMAN; JOINT MOBILITY; KNEE OSTEOARTHRITIS; MEDIATOR RELEASE; NONHUMAN; OSTEOARTHRITIS; OXIDATIVE STRESS; POMEGRANATE; POMEGRANATE JUICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOYBEAN MILK; SYNOVIOCYTE; TREATMENT OUTCOME;

CARTILAGE, ARTICULAR; CATECHIN; CITRUS; CURCUMIN; FLAVONES; GENISTEIN; HUMANS; OSTEOARTHRITIS; PLANT EXTRACTS; POLYPHENOLS; PUNICACEAE; STILBENES;

CITRUS; LYTHRACEAE;

EID: 84867731198     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2012.04.001     Document Type: Review

References (102)

1. Busija L., Bridgett L., Williams S.R., Osborne R.H., Buchbinder R., March L., et al. Osteoarthritis. Best Pract Res Clin Rheumatol 2010, 24(6):757-768.
2. Gore M., Tai K.S., Sadosky A., Leslie D., Stacey B.R. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis. J Med Econ 2011, 14(4):497-507.
3. Bitton R. The economic burden of osteoarthritis. Am J Manag Care 2009, 15(8 Suppl):S230-S235.
4. Sofat N., Ejindu V., Kiely P. What makes osteoarthritis painful? The evidence for local and central pain processing. Rheumatology (Oxford) 2011, 50(12):2157-2165.
5. Goldring M.B., Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011, 23(5):471-478.
6. Krasnokutsky S., Attur M., Palmer G., Samuels J., Abramson S.B. Current concepts in the pathogenesis of osteoarthritis. Osteoarthritis Cartilage 2008, 16(Suppl 3):S1-S3. Review.
7. Sanghi D., Avasthi S., Mishra A., Singh A., Agarwal S., Srivastava R.N. Is radiology a determinant of pain, stiffness, and functional disability in knee osteoarthritis? A cross-sectional study. J Orthop Sci 2011, 16(6):719-725.
8. Umlauf D., Frank S., Pap T., Bertrand J. Cartilage biology, pathology, and repair. Cell Mol Life Sci 2010, 67(24):4197-4211. Review.
9. Samuels J., Krasnokutsky S., Abramson S.B. Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis 2008, 66(3):244-250. Review.
10. Henrotin Y., Lambert C., Couchourel D., Ripoll C., Chiotelli E. Nutraceuticals: do they represent a new era in the management of osteoarthritis? A narrative review from the lessons taken with five products. Osteoarthritis Cartilage 2011, 19(1):1-21.
11. Ziskoven C., Jäger M., Kircher J., Patzer T., Bloch W., Brixius K., et al. Physiology and pathophysiology of nitrosative and oxidative stress in osteoarthritic joint destruction. Can J Physiol Pharmacol 2011, 89(7):455-466.
12. Abramson S.B., Attur M., Amin A.R., Clancy R. Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. Curr Rheumatol Rep 2001, 3(6):535-541. Review.
13. Regan E., Flannelly J., Bowler R., Tran K., Nicks M., Carbone B.D., et al. Extracellular superoxide dismutase and oxidant damage in osteoarthritis. Arthritis Rheum 2005, 52(11):3479-3491.
14. Deberg M., Labasse A., Christgau S., Cloos P., Bang Henriksen D., Chapelle J.P., et al. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2005, 13(3):258-265.
15. Henrotin Y., Kurz B., Aigner T. Oxygen and reactive oxygen species in cartilage degradation: friends or foes?. Osteoarthritis Cartilage 2005, 13(8):643-654. Review.
16. Martel-Pelletier J. Pathophysiology of osteoarthritis. Osteoarthritis Cartilage 1998, 6(6):374-376. Review.
17. Scharstuhl A., Glansbeek H.L., van Beuningen H.M., Vitters E.L., van der Kraan P.M., van den Berg W.B. Inhibition of endogenous TGF-beta during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair. J Immunol 2002, 169(1):507-514.
18. Goldring M.B., Goldring S.R. Osteoarthritis. J Cell Physiol 2007, 213(3):626-634.
19. Amin A.R., Attur M., Abramson S.B. Nitric oxide synthase and cyclooxygenases: distribution, regulation, and intervention in arthritis. Curr Opin Rheumatol 1999, 11:202-209.
20. Fernades J.C., Martel-Pelletier J., Pelletier J.P. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002, 39(1-2):237-246.
21. Mueller M.B., Tuan R.S. Anabolic/catabolic balance in pathogenesis of osteoarthritis: identifying molecular targets. PMR 2011, 3(6 Suppl 1):S3-S11.
22. Sgaglione N.A. Biologic approaches to articular cartilage surgery: future trends. Orthop Clin North Am 2005, 36(4):485-495.
23. Henrotin Y., Kurz B. Antioxidant to treat osteoarthritis: dream or reality?. Curr Drug Targets 2007, 8:347-357.
24. Ahmed S., Wang N., Hafeez B.B., Cheruvu V.K., Haqqi T.M. Punica granatum L. extract inhibits IL-1β-induced expression of matrix metalloproteinases by inhibiting the activation of MAP kinases and NF-κB in human chondrocytes in vitro. J Nutr 2005, 135:2096-2102.
25. Henrotin Y., Clutterbuck A.L., Allaway D., Lodwig E.M., Harris P., Mathy-Hartert M., et al. Biological actions of curcumin on articular chondrocytes. Osteoarthritis Cartilage 2010, 18:141-149.
26. Liacini A., Sylvester J., Li W.Q., Huang W., Dehnade F., Ahmad M., et al. Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res 2003, 288:208-217.
27. Schulze-Tanzil G., Mobasheri A., Sendzik J., John T., Shakibaei M. Effects of curcumin (diferuloylmethane) on nuclear factor kappaB signaling in interleukin-1beta-stimulated chondrocytes. Ann N Y Acad Sci 2004, 1030:578-586.
28. Shakibaei M., John T., Schulze-Tanzil G., Lehmann I., Mobasheri A. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochem Pharmacol 2007, 73:1434-1445.
29. Shakibaei M., Schulze-Tanzil G., John T., Mobasheri A. Curcumin protects human chondrocytes from IL-l1beta-induced inhibition of collagen type II and beta1-integrin expression and activation of caspase-3: an immunomorphological study. Ann Anat 2005, 187:487-497.
30. Clutterbuck A.L., Mobasheri A., Shakibaei M., Allaway D., Harris P. Interleukin-1beta-induced extracellular matrix degradation and glycosaminoglycan release is inhibited by curcumin in an explant model of cartilage inflammation. Ann N Y Acad Sci 2009, 1171:428-435.
31. Mathy-Hartert M., Jacquemond-Collet I., Priem F., Sanchez C., Lambert C., Henrotin Y. Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res 2009, 58:899-908.
32. Chowdhury T.T., Salter D.M., Bader D.L., Lee D.A. Signal transduction pathways involving p38 MAPK, JNK, NFkappaB and AP-1 influences the response of chondrocytes cultured in agarose constructs to IL-1beta and dynamic compression. Inflamm Res 2008, 57:306-313.
33. Shakibaei M., Mobasheri A., Buhrmann C. Curcumin synergizes with resveratrol to stimulate the MAPK signaling pathway in human articular chondrocytes in vitro. Genes Nutr 2011, 6(2):171-179.
34. Lev-Ari S., Strier L., Kazanov D., Elkayam O., Lichtenberg D., Caspi D., et al. Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells. Rheumatology (Oxford) 2006, 45:171-177.
35. Jackson J.K., Higo T., Hunter W.L., Burt H.M. The antioxidants curcumin and quercetin inhibit inflammatory processes associated with arthritis. Inflamm Res 2006, 55:168-175.
36. Toegel S., Wu S.Q., Piana C., Unger F.M., Wirth M., Goldring M.B., et al. Comparison between chondroprotective effects of glucosamine, curcumin, and diacerein in IL-1beta-stimulated C-28/I2 chondrocytes. Osteoarthritis Cartilage 2008, 16:1205-1212.
37. Kuptniratsaikul V., Thanakhumtorn S., Chinswangwatanakul P., Wattanamongkonsil L., Thamlikitkul V. Efficacy and safety of curcuma domestica extracts in patients with knee osteoarthritis. J Altern Complement Med 2009, 15(8):891-897.
38. Belcaro G., Cesarone M.R., Dugall M., Pellegrini L., Ledda A., Grossi M.G., et al. Product evaluation registry of Meriva, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med 2010, 52:55-62.
39. Belcaro G., Cesarone M.R., Dugall M., Pellegrini L., Ledda A., Grossi M.G., et al. Efficacy and safety of Meriva, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev 2010, 15(4):337-344.
40. Ahmed S., Rahman A., Hasnain A., Lalonde M., Goldberg V.M., Haqqi T.M. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Biol Med 2002, 33:1097-1105.
41. Singh R., Ahmed S., Islam N., Goldberg V.M., Haqqi T.M. Epigallocatechin-3-gallate inhibits interleukin-1beta-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor kappaB activation by degradation of the inhibitor of nuclear factor kappaB. Arthritis Rheum 2002, 46:2079-2086.
42. Singh R., Ahmed S., Malemud C.J., Goldberg V.M., Haqqi T.M. Epigallocatechin-3-gallate selectively inhibits interleukin-1beta-induced activation of mitogen activated protein kinase subgroup c-Jun N-terminal kinase in human osteoarthritis chondrocytes. J Orthop Res 2003, 21:102-109.
43. Heinecke L.F., Grzanna M.W., Au A.Y., Mochal C.A., Rashmir-Raven A., Frondoza C.G. Inhibition of cyclooxygenase-2 expression and prostaglandin E2 production in chondrocytes by avocado soybean unsaponifiables and epigallocatechin gallate. Osteoarthritis Cartilage 2010, 18:220-227.
44. Ahmed S. Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise. Arthritis Res Ther 2010, 12:208.
45. Huang G.S., Tseng C.Y., Lee C.H., Su S.L., Lee H.S. Effects of (-)-epigallocatechin-3-gallate on cyclooxygenase 2, PGE(2), and IL-8 expression induced by IL-1beta in human synovial fibroblasts. Rheumatol Int 2010, 30(9):1197-1203.
46. Rasheed Z., Anbazhagan A.N., Akhtar N., Ramamurthy S., Voss F.R., Haqqi T.M. Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes. Arthritis Res Ther 2009, 11:R71.
47. Ahmed S., Wang N., Lalonde M., Goldberg V.M., Haqqi T.M. Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1 beta-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. J Pharmacol Exp Ther 2004, 308:767-773.
48. Adcocks C., Collin P., Buttle D.J. Catechins from green tea (Camellia sinensis) inhibit bovine and human cartilage proteoglycan and type II collagen degradation in vitro. J Nutr 2002, 132:341-346.
49. Vankemmelbeke M.N., Jones G.C., Fowles C., Ilic M.Z., Handley C.J., Day A.J., et al. Selective inhibition of ADAMTS-1, -4 and -5 by catechin gallate esters. Eur J Biochem 2003, 270:2394-2403.
50. Andriamanalijaona R., Kypriotou M., Bauge C., Renard E., Legendre F., Raoudi M., et al. Comparative effects of antioxidants, selenomethionine and epigallocatechin-gallate, on catabolic and anabolic gene expression of articular chondrocytes. J Rheumatol 2005, 32:1958-1967.
51. Katiyar S.K., Raman C. Green tea: a new option for the prevention or control of osteoarthritis. Arthritis Res Ther 2011, 13:121.
52. Sobhi A.B., Mohamad A.O., Mehana E.D., Abdel-Raheim M. The protective effect of green tea extract against the oxidative stress of the experimental arthritic rats. PMJ 2007, 3(1):12-18.
53. Haqqi T.M., Anthony D.D., Gupta S., Ahmad N., Lee M.S., Kumar G.K., et al. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci USA 1999, 96:4524-4529.
54. Yadav M., Jain S., Bhardwaj A., Nagpal R., Puniya M., Tomar R., et al. Biological and medicinal properties of grapes and their bioactive constituents: an update. J Med Food 2009, 12(3):473-484.
55. Dave M., Attur M., Palmer G., Al-Mussawir H.E., Kennish L., Patel J., et al. The antioxidant resveratrol protects against chondrocyte apoptosis via effects on mitochondrial polarization and ATP production. Arthritis Rheum 2008, 58:2786-2797.
56. Csaki C., Mobasheri A., Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther 2009, 11(6):R165.
57. Shakibaei M., Csaki C., Nebrich S., Mobasheri A. Resveratrol suppresses interleukin-1beta-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem Pharmacol 2008, 76:1426-1439.
58. Csaki C., Keshishzadeh N., Fischer K., Shakibaei M. Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem Pharmacol 2008, 75:677-687.
59. Shakibaei M., John T., Seifarth C., Mobasheri A. Resveratrol inhibits IL-1B-induced stimulation of caspase-3 and cleavage of PARP in human articular chondrocytes in vitro. Ann NY Acad Sci 2007, 1095:554-563.
60. Manna S.K., Mukhopadhyay A., Aggarwal B.B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000, 164(12):6509-6519.
61. Estrov Z., Shishodia S., Faderl S., Harris D., Van Q., Kantarjian H.M., et al. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 2003, 102(3):987-995.
62. Holmes-McNary M., Baldwin A.S. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 2000, 60(13):3477-3483.
63. Subbaramaiah K., Chung W.J., Michaluart P., Telang N., Tanabe T., Inoue H., et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998, 273(34):21875-21882.
64. Surh Y.J., Chun K.S., Cha H.H., Han S.S., Keum Y.S., Park K.K., et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 2001, 480-481:243-268.
65. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'?. Eur J Endocrinol 1998, 138:619-620.
66. Soleas G.J., Diamandis E.P., Goldberg D.M. Wine as a biological fluid: history, production, and role in disease prevention. J Clin Lab Anal 1997, 11:287-313.
67. Lei M., Liu S.Q., Liu Y.L. Resveratrol protects bone marrow mesenchymal stem cell derived chondrocytes cultured on chitosan-gelatin scaffolds from the inhibitory effect of interleukin-1beta. Acta Pharmacol Sin 2008, 29:1350-1356.
68. Liu F.C., Hung L.F., Wu W.L., Chang D.M., Huang C.Y., Lai J.H. Chondroprotective effects and mechanisms of resveratrol in advanced glycation end products stimulated chondrocytes. Arthritis Res Ther 2010, 12:R167.
69. Lei M., Wang J.G., Xiao D.M., Fan M., Wang D.P., Xiong J.Y., et al. Resveratrol inhibits interleukin 1β-mediated inducible nitric oxide synthase expression in articular chondrocytes by activating SIRT1 and thereby suppressing nuclear factor-κB activity. Eur J Pharmacol 2012, 674(2-3):73-79.
70. Elmali N., Esenkaya I., Harma A., Ertem K., Turkoz Y., Mizrak B. Effect of resveratrol in experimental osteoarthritis in rabbits. Inflamm Res 2005, 54(4):158-162.
71. Wang J., Gao J.S., Chen J.W., Li F., Tian J. Effect of resveratrol on cartilage protection and apoptosis inhibition in experimental osteoarthritis of rabbit. Rheumatol Int 2011, [Epub ahead of print].
72. Murakami A., Nakamur Y., Torikai K., Tanaka T., Koshiba T., Koshimizu K., et al. Inhibitory effect of citrus nobiletin on phorbol ester-induced skin inflammation, oxidative stress, and tumor promotion in mice. Cancer Res 2000, 60:5059-5066.
73. Sato T., Koike L., Miyata Y., Kirata M., Mimaki Y., Sashida Y., et al. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinase-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells. Cancer Res 2002, 62:1025-1029.
74. Mankin H.J., Lippiello L. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. J Bone Joint Surg Am 1970, 52:424-434.
75. Troeberg L., Nagase H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta 2011, [Epub ahead of print].
76. Nagase J., Kashigawi M. Aggrecanases and cartilage matrix degradation. Arthritis Res Ther 2003, 5:94-103.
77. Imada K., Lin N., Liu C., Lu A., Chen W., Yano M., et al. Nobiletin, a citrus polymethoxy flavonoid, suppresses gene expression and production of aggrecanases-1 and -2 in collagen-induced arthritic mice. Biochem Biophys Res Commun 2008, 373:181-185.
78. Lin N., Sato T., Takayama Y., Mimaki Y., Sashida Y., Yano M., et al. Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochem Pharmacol 2003, 65:2065-2071.
79. Ishiwa J., Sato T., Mimaki Y., Sashida Y., Yano M., Ito A. A citrus flavonoid, nobiletin, suppresses production and gene expression of matrix metalloproteinase 9/gelatinase B in rabbit synovial fibroblasts. J Rheumatol 2000, 27:20-25.
80. Kurowska E.M., Manthey J.A. Hypolipidemic effects and absorption of citrus polymethoxylated flavones in hamsters with diet-induced hypercholesterolemia. J Agric Food Chem 2004, 52(10):2879-2886.
81. Kurowska E.M., Manthey J.A., Casaschi A., Theriault A.G. Modulation of Hepg2 cell net apolipoprotein B secretion by the citrus polymethoxyflavone, tangeretin. Lipids 2004, 39(2):143-151.
82. Whitman S.C., Kurowska E.M., Manthey J.A., Daugherty A. Nobiletin, a citrus flavonoid isolated from tangerines, selectively inhibits class A scavenger receptor-mediated metabolism of acetylated LDL by mouse macrophages. Atherosclerosis 2005, 178(1):25-32.
83. Oben J., Enonchong E., Kothari S., Chambliss W., Garrison R., Dolnick D. Phellodendron and Citrus extracts benefit cardiovascular health in osteoarthritis patients: a double-blind, placebo-controlled pilot study. Nutr J 2008, 7:16.
84. Oben J., Enonchong E., Kothari S., Chambliss W., Garrison R., Dolnick D. Phellodendron and Citrus extracts benefit joint health in osteoarthritis patients: a pilot, double-blind, placebo-controlled study. Nutr J 2009, 8:38.
85. Li R.W., Theriault A.G., Au K., Douglas T.D., Casaschi A., Kurowska E.M., et al. Citrus polymethoxylated flavones improve lipid and glucose homeostasis and modulate adipocytokines in fructose-induced insulin resistant hamsters. Life Sci 2006, 79(4):365-373.
86. Manthey J.A., Grohmann K., Montanari A., Ash K., Manthey C.L. Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes. J Nat Prod 1999, 62(3):441-444.
87. Seeram N.P., Adams L.S., Henning S.M., Niu Y., Zhang Y., Nair M.G., et al. In vitro antiproliferative, apoptotic, and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 2005, 16:369-370.
88. Daniel M. Medicinal plants: chemistry and properties 2006, Science Publishers, Enfeld, NH.
89. Shukla M., Gupta K., Rasheed Z., Khan K.A., Haqqi T.M. Bioavailable constituents/metabolites of pomegranate (Punica granatum L) preferentially inhibit COX2 activity ex vivo and IL-1β-induced PGE2 production in human chondrocytes in vitro. J Inflamm 2008, 5:9.
90. Rasheed Z., Akhtar N., Haqqi T.M. Pomegranate extract inhibits the interleukin-1β-induced activation of MKK-3, p38α-MAPK, and transcription factor Runx2 in human osteoarthritis chondrocytes. Arthritis Res Ther 2010, 12:R195.
91. Garbacki N., Angenot L., Bassleer C., Damas J., Tits M. Effects of prodelphinidins isolated from Ribes nigrum on chondrocyte metabolism and COX activity. Naunyn Schmiedebergs Arch Pharmacol 2002, 365:434-441.
92. Hadipour-Jahromy M., Mozaffari-Kermani R. Chondroprotective effects of pomegranate juice on monoiodoacetate-induced osteoarthritis of the knee joint of mice. Phytother Res 2010, 24(2):182-185.
93. Claassen H., Briese V., Manapov F., Nebe B., Schunke M., Kurz B. The phytoestrogens daidzein and genistein enhance the insulin-stimulated sulfate uptake in articular chondrocytes. Cell Tissue Res 2008, 333:71-79.
94. Koelling S., Miosge N. Sex differences of chondrogenic progenitor cells in late stages of osteoarthritis. Arthritis Rheum 2010, 62(4):1077-1087.
95. Tanamas S.K., Wijethilake P., Wluka A.E., Davies-Tuck M.L., Urquhart D.M., Wang Y., et al. Sex hormones and structural changes in osteoarthritis: a systematic review. Maturitas 2011, 69(2):141-156. Review.
96. Hooshmand S., Soung do Y., Lucas E.A., Madihally S.V., Levenson C.W., Arjmandi B.H. Genistein reduces the production of proinflammatory molecules in human chondrocytes. J Nutr Biochem 2007, 18:609-614.
97. Claassen H., Schlüter M., Schunke Michael, Kurz B. Influence of 17β-estradiol and insulin on type II collagen and protein synthesis of articular chondrocytes. Bone 2006, 39:310-317.
98. Cheng C.C., Chen Y.H., Chang W.L., Yang S.H., Chang D.M., Lai J.H., et al. Phytoestrogen bavachin mediates anti-inflammation targeting ικβ kinase- ικβα-NF-κB signaling pathway in chondrocytes in vitro. Eur J Pharmacol 2010, 636:181-188.
99. Ham K.D., Oegema T.R., Loeser R.F., Carlson C.S. Effects of long-term estrogen replacement therapy on articular cartilage IGFBP-2, IGFBP-3, collagen and proteoglycan levels in ovariectomized cynomolgus monkeys. Osteoarthritis Cartilage 2004, 12(2):160-168.
100. Ham K.D., Carlson C.S. Effects of estrogen replacement therapy on bone turnover in subchondral bone and epiphyseal metaphyseal cancellous bone of ovariectomized cynomolgus monkeys. J Bone Miner Res 2004, 19(5):823-829.
101. Arjmandi B.H., Khalil D.A., Lucas E.A., Smith B.J., Sinichi N., Hodges S.B., et al. Soy protein may alleviate osteoarthritis symptoms. Phytomedicine 2004, 11(7-8):567-575.
102. Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006, 354(8):795-808.